A B S T R A C T The mechanism of stimulus-response coupling in human platelets was investigated with a new instrument that simultaneously monitors aggregation and secretion in the same sample of plateletrich plasma. When platelets were stimulated by high concentrations of ADP, secretion began only after aggregation was almost complete. With lower concentrations of ADP or with epinephrine, biphasic aggregation was observed, and secretion began simultaneously with, or slightly after, the second phase of aggregation. When platelets were stimulated with high concentrations of y-thrombin or A23187, secretion and aggregation began essentially together. With very low concentrations of y-thrombin or A23187, biphasic aggregation was observed with secretion paralleling the second phase. At every concentration of collagen, secretion and aggregation appeared to be parallel events. Under every condition where the beginning of secretion lagged behind aggregation, secretion was dependent upon aggregation and was inhibited by indomethacin; this is referred to as aggregation-mediated platelet activation. When secretion began at the same time as aggregation, it also occurred in the absence of aggregation and was not blocked by indomethacin; this is referred to as directly induced platelet activation. These observations are -consistent with a simple model of platelet stimulusresponse coupling that includes two mechanisms for activation; aggregation-mediated activation is inhibited by indomethacin, while direct activation does not depend upon aggregation and is not inhibited by indomethacin. Secretion and second wave aggregation appear to be parallel events, with little evidence for second wave aggregation being a consequence of secretion as usually described.
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We have therefore studied the response of platelets to several types of stimuli with a new instrument to measure shape change, aggregation, and secretion simultaneously in the same sample (4, 5) of plateletrich plasma. We used indomethacin, an inhibitor of prostaglandin synthesis and the "second wave" of aggregation, to distinguish different aspects of the responses. We propose a model of stimulus-response coupling that includes two mechanisms of platelet activation; one is mediated by aggregation and is inhibited by indomethacin, while the other is independent of aggregation and is not inhibited by indomethacin.
METHODS
Preparation of platelet-sich plasma. Blood was collected by venipuncture from healthy volunteers into 0.1 vol of 3.8% trisodium citrate. All donors denied taking any drugs for at least 1 wk before phlebotomy. Platelet-rich plasma was prepared by centrifugation of the whole blood at 300 g for 20 min at 25°C. Platelet-poor plasma was obtained by centrifugation of an aliquot of platelet-rich plasma for 5 min in an Eppendorf microfuge (model 320, Brinkmann Instruments, Inc., Westbury, N. Y.).
Simultaneous measurement of shape change, aggregation, and secretion. The continuous recording ofplatelet function was carried out with a new instrument that continuously and simultaneously monitors secreted ATP and light transmittance (shape change and aggregation) in the same sample. This instrument, described in detail elsewhere (4, 5) , utilizes the luminescent firefly luciferase system for detection of secreted ATP (6, 7), while aggregation is measured by the usual turbidometric method (8) . The geometry of the optics, as well as the use of near-infrared light for the Charo et al. (7) . The aggregation trace was calibrated with platelet-free plasma (theoretical maximal aggregation) at about half the full chart width (see Fig. 1 The results presented here are representative of many experiments with platelet-rich plasma obtained from 25 different donors. The data within a figure are from a single sample of platelet-rich plasma, and, in addition, comparisons between figures are valid because both aggregation and secretion curves are standardized to maximum responses (see preceding paragraph), thereby normalizing differences in platelet counts of different donors. Results have been highly consistent except for tl%e well-known variation among donors for biphasic aggregation (9); from a single sample of platelet-rich plasma, biphasic aggregation is fully reproducible, but the concentration of stimulus required for biphasic aggregation is slightly different for each sample of platelet-rich plasma. Although biphasic aggregation may be an in vitro artifact (10) , it is believed to reflect important physiological functions and is especially important as the only in vitro parameter of platelet function that is dependent upon prostaglandin synthesis. We have also observed some variation between donors in the rate of response of platelets to ADP; the traces selected for Fig. 1 H-60 __ FIGURE 1 Simultaneous measurements of aggregation and secretion induced by high levels of stimuli added to platelet-rich plasma as described in Methods. Secretion of ATP (lower traces) was measured by the firefly luminescence assay, with the gaini of the instrument set so that maximum release with thrombin gave half:chart deflection (indicated by MAX). The decrease in the signal seen at the end of some curves does not represent uptake o0 metabolism of ATP by platelets, but is due to the well-known propertN of the assay system to show a decay in luminescence (23, 24) . Aggregation (uppem traces) was measured simultaneously in the same cuvette, with the limit set with platelet-free plasma (PFP, as indicated. Reactions were initiated by addition of the stimulus. In the second set of traces, the stirring motor was turned off to prevent aggregation. The first four experiments were recorded at 30 s/inch (space between vertical bars) and the fifth was at 60 s/inch. tion was examined by comparison of curves with different concentrations of stimuli with and without indomethacin, an inhibitor of prostaglandin synthesis and "second wave" aggregation. Fig. 2 shows the effects of indomethacin on aggregation and secretion induced by levels of ADP low enough to cause two waves of aggregation or by saturating levels. Indomethacin clearly blocked both second wave aggregation and secretion. Similar results were obtained with epinephrine-stimulated platelets, where biphasic aggregation was more distinct (Fig. 3) . Note that the second wave of aggregation preceeds the onset of detectable secretion, and again indomethacin blocks both secretion and second wave aggregation. With thrombin as the stimulus, two different relationships between aggregation and secretion were observed (Fig. 4) . At low levels of thrombin, aggregation was biphasic, with secretion detectable only with the beginning of the second wave of aggregation; both secretion and second wave aggregation were blocked by indomethacin. At saturating levels of thrombin, a single wave of aggregation was observed, with secretion and aggregation beginning simultaneously; indomethacin had essentially no effect. Similar results were seen with stimulation by the divalent cation ionophore A23187 (Fig. 5) ; at low levels there were two waves of aggregation, with secretion and the second wave of aggregation blocked by indomethacin, while at high levels indomethacin had little effect.
A somewhat different pattern of responses was observed with collagen stimulation (Fig. 6) . Secretioñ~~~~~~~~~~~~E Effect of indomethacin on thrombin-induced secretion and aggregation. The experiments were as described in Fig. 2 been due to generation of thrombin. The failure of the antithrombin-heparin complex to give similar inhibition suggests either that hirudin inhibits something other than thrombin or, if thrombin is involved, that it may be generated on the platelet surface where it is not accessible to the larger inhibitor.
DISCUSSION
The progress-time curves of secretion and aggregation presented depict the precise temporal relationship between secretion, shape change, and aggregation. Our data suggest that there are two fundamentally different ways of inducing secretion. One way is dependent upon aggregation, is blocked by indomethacin, and has a substantial lag between induction of aggregation and secretion; the other mechanism is independent of aggregation, is not affected by indomethacin, and shows simultaneous aggregation and secretion. Some stimuli (e.g., ADP and epinephrine) are capable of inducing only aggregation-dependent secretion. Secretion induced by these agents is inhibited by indomethacin and occurs well after aggregation under all conditions and regardless of concentration of stimulus (ADP curve in Fig. 1 ).
Other stimuli (e.g., thrombin and A23187) induce aggregation-dependent secretion at very low levels of stimulus but are also capable of inducing aggregationindependent secretion at higher levels of stimulus. An important feature of these curves is the relationship between second wave aggregation and secretion, which begin together, with second wave aggregation actually appearing to slightly preceed secretion in some traces (Fig. 3) . It thus appears that second wave aggregation and secretion are parallel events and may not be causally related. This result suggests that the widely held concept that second wave aggregation is the consequence of secreted substances (i.e., an inter-platelet positive feedback) may be incorrect (14) (15) (16) . Although it is possible that some active substance (e.g., a prostaglandin intermediate) is released before ATP,2 or that at the time of second wave aggregation the platelets have become exquisitely sensitive to traces of secreted substances, we suggest an alternative interpretation. A model that is consistent with our data, that does not presume inter-platelet "feedback" reactions, and that represents a somewhat different way of considering stimulusresponse coupling in platelets is shown in Fig. 7 .
We postulate two distinct mechanisms leading to 2 It is believed, but has not been conclusively proved, that secreted substances are stored in the dense bodies and secreted as a packet, so that measurement of any one represents all others. Prostaglandin intermediates are not stored in dense bodies and may be released with a different time course. platelet activation; (a) an aggregation-mediated, indomethacin-sensitive mechanism, and (b) a direct activation mechanism that bypasses the indomethacinsensitive, aggregation step. Our data suggest that secretion and secondary aggregation follow platelet activation3 as parallel events. We speculate that intra-platelet phenomena lead to second wave aggregation and that inter-platelet feedback phenomena are not required as generally believed. While inter-platelet reactions are certainly possible (perhaps even likely under some conditions), such second order effects need not be considered to explain the results presented here. In addition, with aggregation-mediated activation, the circumstance where inter-platelet phenomena have been considered significant, the amount of ATP secreted is much less than with direct activation. This seems inconsistent with a positive feedback mechanism, but is consistent with our model if it is assumed that aggregation-mediated activation is not as complete as direct activation. Although the model in Fig. 7 is independent of actual intermediates or second messengers, we have considered how the overall scheme might relate to intermediates that have been implicated in stimulusresponse coupling in platelets. There is some evidence for a central role for Ca2+ in regulation of platelet function (17) (18) (19) (20) , so that activation may involve an intracellular Ca2+ flux. One line of evidence for a Ca2+ flux is the ability of the divalent cation ionophore to activate platelets (17) (18) (19) , and the ability of A23187 to cause shape change and primary aggregation suggests that these processes may also involve Ca2 . Since shape change and aggregation can be seen in the absence of secretion, this would involve Ca2+ in a different compartment or simply as a weaker flux, consistent with Holmsen's suggestion that graded Ca2+ fluxes lead to graded responses (21) . It should be noted, however, that this key role of an intracellular Ca2+ flux is still largely hypothetical.
In the model, we suggest that prostaglandin synthesis may be involved in two ways. Inhibition of aggregation-mediated activation by indomethacin, a known inhibitor of cyclooxygenase, implies that prostaglandin synthesis is a necessary intermediate in this mechanism of activation. However, thrombin and A23187 stimulate very rapid prostaglandin synthesis even though platelet activation by these agents is not inhibited by indomethacin, suggesting that prostaglandin synthesis may also be a consequence of platelet activation. Stimuli that induce the greatest yield of secretion (e.g., thrombin) also induce the greatest prostaglandin synthesis (22) , while stimuli that induce less secretion (e.g., ADP) also induce (under most circumstances this will be aggregation without secretion), whereas secondary aggregation is aggregation by fully activated platelets (under most circumstances this will be accompanied by secretion). We define an "activated" platelet phenomenologically as one that secretes, rapidly synthesizes prostaglandins, and undergoes secondary aggregation. Since primary and secondary aggregation are frequently not distinguishable by an aggregometer trace, secretion is usually the best indicator of platelet activation. less prostaglandin synthesis (22 under these conditions a substantial part of the observed secretion must be due to the second order effects of substances released from collagen-stimulated platelets. The contribution of these second order effects to total secretion would be inhibited by indomethacin if they were due to either released prostaglandin intermediates or secreted ADP (or any agent that activated by an aggregation-mediated mechanism).
In conclusion, the stimuli we have studied can be categorized according to the mechanism by which they activate platelets. ADP and epinephrine activate only by an aggregation-mediated mechanism. Thrombin and A23187 activate by either an aggregation-mediated or a direct activation mechanism, depending upon the concentration. Collagen appears to activate only by the direct activation mechanism. Secondary effects due to released substances appear to be important only with collagen. It should be emphasized that our proposal that secreted substances do not play a major role with most stimuli is based not on the absence of detectable nucleotides before second wave aggregation, but rather on the consistency of a model that considers second wave aggregation and secretion as parallel events and that does not require the previously postulated involvement of secreted substances.
